Skip to content
value.today

Meridian Bioscience: financial analysis

Ratios worked out from 10 fiscal years of Meridian Bioscience's statements, compared with 87 companies in Diagnostics and Research.

The newest statement on file is for fiscal 2022. The figures below describe that year, not Meridian Bioscience today.

Operating margin, 2022
16.3%
Diagnostics and Research: -2.4%
Return on equity, 2022
12.2%
Diagnostics and Research: -5.4%
Revenue growth, 3 years a year, 2022
18.3%
Diagnostics and Research: 3.6%
Debt to equity, 2022
0.07×
Diagnostics and Research: 0.57×

Meridian Bioscience scorecard#

Passes 16 of the 18 checks that could be worked out: strongest in financial health (5 of 5), weakest in growth (5 of 6). Fiscal year 2022.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth5 of 6
    • ✓Revenue grew in the newest year4.8%Revenue up 4.8% in fiscal 2022.
    • ✓Revenue up more than 5% a year over three years18.3%18.3% a year over the three years to fiscal 2022.
    • ✓Faster growth over three years than its peers' median18.3%18.3% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year0.96 vs 1.62Diluted EPS 0.96 in fiscal 2022 against 1.62 the year before (report's currency).
    • ✓Net income higher than five years earlier$42 M$42 M in fiscal 2022 against $22 M in 2017.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2022.
  • Profitability5 of 6
    • ✓Profitable in the newest year$42 MNet income $42 M in fiscal 2022.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2022.
    • ✓Operating margin above its peers' median16.3%16.3% against Diagnostics and Research's median of -2.4% (66 companies).
    • ✗Return on equity above 15%12.2%12.2% in fiscal 2022.
    • ✓Return on invested capital above 10%13.1%13.1% in fiscal 2022.
    • ✓Operating margin wider than three years earlier16.3%16.3% in fiscal 2022 against 16.3% in 2019.
  • Financial health5 of 5
    • ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.63 at the end of fiscal 2022.
    • ✓Debt below equity0.1×Debt to equity 0.07 at the end of fiscal 2022.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $56 M at the end of fiscal 2022.
    • ✓Operating income covers interest five times45.7×Operating income 45.7 times interest in fiscal 2022.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2022.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.8%Diluted shares up 0.8% in fiscal 2022.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2022 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Revenue has grown 3 years in a row.
  • Free cash flow has been positive 14 years in a row.
  • More cash than debt: net cash of $56 million.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 9
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsyes
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin roseno
  • Asset turnover roseyes

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin12.8%Asset turnover0.73×Assets to equity1.31×Return on equity12.2%

Profitability#

Meridian Bioscience: profitability by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Gross margin56.6%63.3%61.6%59.1%61.4%55.7%52%
Operating margin16.3%29.3%24.2%16.3%14.8%-2.4%78%
Net margin12.8%22.5%18.2%12.1%11.2%-3.6%78%
Return on equity12.2%24.8%21.1%13.3%13.8%-5.4%76%
Return on assets9.3%16.7%12.6%8.5%9.5%-7.1%86%
Return on invested capital13.1%24.4%20.4%13.8%15.3%9.3%73%

Growth#

Meridian Bioscience: growth by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Revenue growth4.8%25.3%26.2%-5.9%6.4%6.6%42%
Revenue growth, 3 years a year18.3%14.2%8.1%0.8%3.1%3.6%79%
Revenue growth, 5 years a year10.7%10.2%5.4%1.3%2.5%9.7%57%
Net income growth-40.5%54.6%89.5%2.2%10.6%9.0%12%
Earnings per share growth-40.7%51.4%87.7%1.8%9.8%6.0%9%

Financial strength#

Meridian Bioscience: financial strength by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Debt to equity0.07×0.18×0.28×0.40×0.26×0.57×97%
Net debt$-56 M$10 M$15 M$13 M$-15 M$270 M95%
Net debt to EBITDA-0.80×0.09×0.20×0.31×-0.37×2.20×86%
Interest cover45.71×49.48×23.32×16.86×20.78×-3.31×100%
Current ratio3.63×4.09×3.09×6.92×5.75×1.97×68%
Equity share of assets79.5%73.0%61.1%58.7%69.8%51.8%84%

Cash#

Meridian Bioscience: cash by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Free cash flow$74 M$49 M$45 M$32 M$31 M$-2 M69%
Free cash flow margin22.1%15.3%17.6%16.1%14.3%4.7%93%
Cash conversion194.0%93.6%103.9%148.4%145.9%169.7%67%
Capital spending share of revenue2.6%5.8%1.3%1.9%2.0%3.3%—

Shareholder returns#

Meridian Bioscience: shareholder returns by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Dividend payout—0.0%0.0%43.5%88.8%23.0%—
Change in share count0.8%1.9%0.6%0.3%0.4%2.8%63%

Efficiency#

Meridian Bioscience: efficiency by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Asset turnover0.73×0.74×0.69×0.70×0.85×0.63×65%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Meridian Bioscience's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 87 companies in Diagnostics and Research that Meridian Bioscience is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Meridian Bioscience